The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Three immune checkpoint inhibitors including a dual checkpoint blockade regimen, four BRAF or MEK targeted agents including combination regimens, and a viral therapy have gained regulatory approval for malignant melanoma since 2011. Numerous label expansions for currently marketed therapies are expected to further shape the malignant melanoma market, and with emerging combination therapies demonstrating impressive results, the malignant melanoma market will become increasingly competitive as therapies compete for patient share and sales.
Questions Answered:
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 28 country-specific interviews with thought leaders. We also surveyed malignant melanoma specialists (including dermatologists) in each market on their treatment practices.
Epidemiology: Diagnosed incidence of malignant melanoma by stage of disease and resectability. Clinical and market-relevant drug-treatable populations.
Population segments in market forecast: Resectable (stage IIb-III), first-line unresectable or metastatic BRAF-wild-type, first-line unresectable or metastatic BRAF-mutation-positive, second-line unresectable or metastatic BRAF-wild-type, second-line unresectable or metastatic BRAF-mutation-positive, third-line unresectable or metastatic BRAF- wild-type, third- and fourth-line unresectable or metastatic BRAF-mutation-positive.
Emerging therapies: Phase II: 32 drugs; Phase III: 6 drugs; registered: 1 drugs. Coverage of 28 select Phase I products.